Literature DB >> 28161844

Increased plasma level of catestatin might be associated with poor prognosis in hemodialysis patients.

Huaibin Sun1, Wanhua Xian1, Lina Geng1, Engang Li1, Zhiguo Peng1, Jun Tian2.   

Abstract

PURPOSE: Cardiac complication is a major cause of death in hemodialysis patients. The aim of the study was to determine the relationship between plasma catestatin level and cardiac death in those people.
METHODS: A total of 330 maintenance hemodialysis patients were included. Blood samples were collected. Plasma catestatin level was detected by enzyme-linked immunosorbent assay. Fluid status of each patient was expressed by overhydration to total body weight ratio and daily diuresis. Each patient was followed-up for 36 months, unless some of them died in the follow-up period.
RESULTS: In the follow-up period, only one hemodialysis patient was lost, 29 patients were died of cardiovascular diseases, 28 patients were died of other diseases and remaining 272 patients survived. Logistic multivariate regression analysis revealed that patients with plasma catestatin level ≥1.9 ng/ml were associated with increased cardiac death risk (RR 6.13, 95% CI 2.54, 18.45), and survival analysis also showed that cardiac death rate in patients with plasma catestatin level ≥1.9 ng/ml was elevated than that in patients with plasma catestatin level <1.9 ng/ml (P < 0.001). In addition, overhydration to total body weight ratio and daily diuresis both had significant linear correlations with plasma catestatin level (r = 0.502, P < 0.001 and r = -0.338, P < 0.001).
CONCLUSION: Circulating catestatin concentration might be an independent cardiac prognostic indicator in hemodialysis patients. Fluid status might be involved in the prognostic forecasting process.

Entities:  

Keywords:  Cardiac complication; Cardiac death; Catestatin; Hemodialysis; Prognosis

Mesh:

Substances:

Year:  2017        PMID: 28161844     DOI: 10.1007/s11255-017-1528-8

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  23 in total

1.  'United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States.

Authors:  Allan J Collins; Robert N Foley; Blanche Chavers; David Gilbertson; Charles Herzog; Kirsten Johansen; Bertram Kasiske; Nancy Kutner; Jiannong Liu; Wendy St Peter; Haifeng Guo; Sally Gustafson; Brooke Heubner; Kenneth Lamb; Shuling Li; Suying Li; Yi Peng; Yang Qiu; Tricia Roberts; Melissa Skeans; Jon Snyder; Craig Solid; Bryn Thompson; Changchun Wang; Eric Weinhandl; David Zaun; Cheryl Arko; Shu-Cheng Chen; Frank Daniels; James Ebben; Eric Frazier; Christopher Hanzlik; Roger Johnson; Daniel Sheets; Xinyue Wang; Beth Forrest; Edward Constantini; Susan Everson; Paul Eggers; Lawrence Agodoa
Journal:  Am J Kidney Dis       Date:  2012-01       Impact factor: 8.860

2.  Long-term Complications in Hemodialysis.

Authors:  C R Blagg
Journal:  Saudi J Kidney Dis Transpl       Date:  2001 Oct-Dec

3.  Usefulness of catestatin to predict malignant arrhythmia in patients with acute myocardial infarction.

Authors:  Zhiqiang Pei; Dengfeng Ma; Lei Ji; Jing Zhang; Jinsheng Su; Weizhen Xue; Xiaoping Chen; Weishu Wang
Journal:  Peptides       Date:  2014-03-11       Impact factor: 3.750

4.  Hypotension and Frequent Hemodialysis: Clarification Requested Regarding the KDOQI Hemodialysis Adequacy Guideline 2015 Update.

Authors:  Ann Mancini
Journal:  Am J Kidney Dis       Date:  2016-03       Impact factor: 8.860

5.  Formation of the catecholamine release-inhibitory peptide catestatin from chromogranin A. Determination of proteolytic cleavage sites in hormone storage granules.

Authors:  C V Taylor; L Taupenot; S K Mahata; M Mahata; H Wu; S Yasothornsrikul; T Toneff; C Caporale; Q Jiang; R J Parmer; V Y Hook; D T O'Connor
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

6.  Cardiac Troponin T and Hydration Status as Prognostic Markers in Hemodialysis Patients.

Authors:  Krzysztof Hoppe; Krzysztof Schwermer; Patrycja Klysz; Dorota Radziszewska; Peter Sawatiuk; Ewa Baum; Jolanta Kaczmarek; Magdalena Roszak; Malgorzata Kaluzna; Bengt Lindholm; Krzysztof Pawlaczyk; Andrzej Oko
Journal:  Blood Purif       Date:  2015       Impact factor: 2.614

Review 7.  Chronic complications in hemodialysis: correlations with primary renal disease.

Authors:  I A Checheriţă; Flavia Turcu; R F Dragomirescu; A Ciocâlteu
Journal:  Rom J Morphol Embryol       Date:  2010       Impact factor: 1.033

8.  Plasma levels and potential roles of catestatin in patients with coronary heart disease.

Authors:  Lin Liu; Wenhui Ding; Feng Zhao; Libin Shi; Yongzheng Pang; Chaoshu Tang
Journal:  Scand Cardiovasc J       Date:  2013-05-20       Impact factor: 1.589

9.  The Effect of BCAA and ISO-WHEY Oral Nutritional Supplements on Dialysis Adequacy.

Authors:  Effat Afaghi; Ali Tayebi; Abbas Ebadi; Vahid Sobhani; Behzad Einollahi; Mehdi Tayebi
Journal:  Nephrourol Mon       Date:  2016-09-05

10.  Overhydration measured by bioimpedance analysis and the survival of patients on maintenance hemodialysis: a single-center study.

Authors:  Ye Jin Kim; Hong Jae Jeon; Yoo Hyung Kim; Jaewoong Jeon; Young Rok Ham; Sarah Chung; Dae Eun Choi; Ki Ryang Na; Kang Wook Lee
Journal:  Kidney Res Clin Pract       Date:  2015-11-11
View more
  3 in total

Review 1.  Role of Catestatin in the Cardiovascular System and Metabolic Disorders.

Authors:  Ewa Zalewska; Piotr Kmieć; Krzysztof Sworczak
Journal:  Front Cardiovasc Med       Date:  2022-05-19

Review 2.  Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers.

Authors:  Angelo Corti; Fabrizio Marcucci; Tiziana Bachetti
Journal:  Pflugers Arch       Date:  2017-10-10       Impact factor: 3.657

3.  Plasma Catestatin Levels and Advanced Glycation End Products in Patients on Hemodialysis.

Authors:  Mirko Luketin; Maja Mizdrak; Dijana Boric-Skaro; Dinko Martinovic; Daria Tokic; Marino Vilovic; Daniela Supe-Domic; Tina Ticinovic Kurir; Josko Bozic
Journal:  Biomolecules       Date:  2021-03-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.